Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Inc (NASDAQ: INSM) is a global biopharmaceutical leader developing innovative therapies for rare pulmonary diseases and chronic inflammatory conditions. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and therapeutic advancements.
Access real-time information about Insmed's FDA submissions, partnership announcements, and research breakthroughs. Our curated collection includes updates on ARIKAYCE commercialization, brensocatib clinical studies, and novel inhalation technologies like TPIP platform developments.
Key content categories include treatment approvals, scientific conference presentations, patent filings, and manufacturing expansions. All materials are sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page for streamlined access to Insmed's latest developments in targeted pulmonary therapy and rare disease research. Check regularly for critical updates affecting treatment accessibility and clinical progress.
Insmed reported a strong second quarter of 2022, with total revenue of $65.2 million, a 44% year-over-year growth. The revenue came mainly from ARIKAYCE, contributing $47.2 million in U.S. sales and $15.8 million from Japan. Despite a net loss of $95.6 million or $0.80 per share, the company reiterated its forecast of at least 30% revenue growth for the full year and plans to maintain financial operations through 2024. Clinical programs are progressing on schedule, with significant milestones anticipated in the coming months.
Insmed Incorporated (Nasdaq:INSM) will release its Q2 2022 financial results on August 4, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call by dialling (888) 210-2654 for U.S. callers and (646) 960-0278 internationally. A replay will be available until September 3, 2022. Insmed focuses on developing therapies for serious and rare diseases and has a first-in-disease therapy approved in multiple regions.
On July 8, 2022, Insmed Incorporated (Nasdaq: INSM) announced inducement awards to 18 employees, a move approved by the Compensation Committee under NASDAQ Listing Rule 5635(c)(4). These new hires received options to purchase 146,070 shares of common stock at $20.89 each, the closing price on July 1, 2022. The options have a 10-year term with a four-year vesting schedule, promoting employee retention. Insmed, based in Bridgewater, New Jersey, focuses on therapies for serious and rare diseases and has a growing pipeline of investigational treatments.
Insmed Incorporated (Nasdaq: INSM) announced that it has granted inducement awards to 24 new employees as part of their employment offer. The approved awards, compliant with NASDAQ Listing Rule 5635(c)(4), include options to purchase 158,530 shares of common stock at an exercise price of $17.93 per share, equivalent to the closing price on June 1, 2022. The options have a 10-year term and a four-year vesting schedule. Insmed is focused on therapies for serious and rare diseases, with a strong commitment to enhancing patient lives.
Insmed has appointed Drayton Wise as the new Chief Commercial Officer, effective May 23, 2022. He will lead global commercial functions and continue overseeing the ARIKAYCE franchise. This strategic move comes as Insmed prepares for significant milestones, including expanding ARIKAYCE's market reach and launching new products like brensocatib. Drayton has been pivotal in building Insmed's commercial organization since joining in 2014. Will Lewis, CEO, expressed confidence in Wise's leadership during this critical phase.
Insmed Incorporated (Nasdaq: INSM) presented new findings at the ATS 2022 International Conference, showcasing significant benefits of ARIKAYCE and brensocatib. A retrospective study revealed a reduction in all-cause hospitalizations from 35.9% to 23.0% in patients following ARIKAYCE treatment, with similar improvements in respiratory-related hospitalizations. Additionally, post-hoc analyses of the WILLOW study indicated a favorable benefit-risk profile for brensocatib, noting a low number needed to treat (NNT) of 6-7 and a negative number needed to harm (NNH), suggesting a lower risk of severe adverse events compared to placebo.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The event is scheduled for on-demand viewing on May 24, 2022, at 7:00 a.m. ET, accessible through the company's investor relations site. Insmed is known for its first-in-disease therapy for chronic lung disease and has a pipeline aimed at unmet medical needs in inflammatory and pulmonary disorders. The webcast will be available for 30 days post-presentation.
On May 6, 2022, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 10 new employees as per NASDAQ Listing Rule 5635(c)(4). These awards include options to purchase 70,080 shares of common stock at $22.45 per share, the closing price on May 2, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq:INSM) reported strong Q1 2022 results, achieving 32% year-over-year growth with total revenue of $53.1 million, driven by ARIKAYCE sales of $40.8 million in the U.S. The company maintains its 2022 revenue guidance of at least 30% growth and a cash runway into 2024. Seven clinical trials are ongoing, including the Phase 3 ASPEN study for brensocatib. Despite a net loss of $94.6 million for the quarter, Insmed's financial position remains strong as it continues to invest in expansion and research initiatives.
Insmed, a biopharmaceutical company focused on rare diseases, plans to release its Q1 2022 financial results on May 5, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call via phone or through a live webcast on the company's website. Insmed aims to transform lives with innovative therapies and is progressing in various serious unmet medical needs.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
